Navigation Links
MonoSol Rx Issued Strategic US Patent Governing the Production of Pharmaceutical Films Containing Specific Drugs and Drug Classes
Date:4/4/2011

WARREN, N.J., April 4, 2011 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,897,080 from the United States Patent and Trademark Office (USPTO). The patent provides intellectual property protection for the Company's methods of pharmaceutical film preparation along with the incorporation of specific drugs and polymer components.

Among the active categories covered in the patent are opiate and opiate derivatives such as buprenorphine and naloxone, anti-emetics such as ondansetron and granisetron hydrochloride, analgesics such as fentanyl, anti-migraines such as triptans, and anti-diabetics.  Polymer components covered by the patent include carboxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and polyethylene oxide.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "This latest patent provides undeniable affirmation that MonoSol Rx has the leading IP position in the development of pharmaceutical films and that our PharmFilm® technology is the industry standard for film drug delivery.  Not only does this patent cover numerous actives and polymer components, but it also ensures that MonoSol Rx has process protection for the manufacturing of single and multi-layer films delivering a wide range of drug classifications through buccal and sublingual administration."  

Mr. Schobel continued, "Coupled with our prior patents, MonoSol Rx's growing intellectual property portfolio offers clear competitive advantages to our current and prospective partners who view PharmFilm® as an ideal vehicle for delivering small or large molecules as well as sensitive prescription drug targets."

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm® technology, and two recent FDA approvals - Zuplenz® (ondansetron) oral soluble film 4 mg and 8 mg, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone®  (buprenorphine and naloxone) sublingual film 2 mg/0.5 mg and 8 mg/2 mg CIII, the first sublingual film product for the treatment of opioid dependence.  

MonoSol Rx's commercialization strategy for all PharmFilm® products is to partner with the innovator or other specialty pharma companies that can sell-in and manage product sales and marketing.  PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs). For existing and future partners, PharmFilm® formulations can also represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.  For press releases and other company information visit www.monosolrx.com.

Contacts:
MonoSol Rx
Keith Kendall, Executive Vice President
(732) 564-5000

The Ruth Group (on behalf of MonoSol Rx)
Jason Rando (media)
(646) 536-7025
jrando@theruthgroup.com

Joshua Drumm (investors)
(646) 536-7006
jdrumm@theruthgroup.com  


'/>"/>
SOURCE MonoSol Rx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film
2. MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010
3. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
4. MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films
5. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
6. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
7. Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs
8. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
9. Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued
10. Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate
11. Sixth U.S. Patent Issued to Dyadic International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-na├»ve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):